Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors.
Sun Z, Lethé B, Zhang Y, Russo V, Colau D, Stroobant V, Boon T, van der Bruggen P. Sun Z, et al. Among authors: russo v. Cancer Immunol Immunother. 2006 Jun;55(6):644-52. doi: 10.1007/s00262-005-0066-x. Epub 2005 Sep 27. Cancer Immunol Immunother. 2006. PMID: 16187088 Free PMC article.
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.
Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Liénard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jäger E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T. Marchand M, et al. Among authors: russo v. Int J Cancer. 1999 Jan 18;80(2):219-30. doi: 10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.0.co;2-s. Int J Cancer. 1999. PMID: 9935203 Clinical Trial.
Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients.
Fontana R, Bregni M, Cipponi A, Raccosta L, Rainelli C, Maggioni D, Lunghi F, Ciceri F, Mukenge S, Doglioni C, Colau D, Coulie PG, Bordignon C, Traversari C, Russo V. Fontana R, et al. Among authors: russo v. Blood. 2009 Feb 19;113(8):1651-60. doi: 10.1182/blood-2008-07-168666. Epub 2008 Dec 12. Blood. 2009. PMID: 19074732 Free article. Clinical Trial.
IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma.
Lorenzi S, Forloni M, Cifaldi L, Antonucci C, Citti A, Boldrini R, Pezzullo M, Castellano A, Russo V, van der Bruggen P, Giacomini P, Locatelli F, Fruci D. Lorenzi S, et al. Among authors: russo v. PLoS One. 2012;7(10):e46928. doi: 10.1371/journal.pone.0046928. Epub 2012 Oct 5. PLoS One. 2012. PMID: 23071666 Free PMC article.
Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies.
Tanzarella S, Lionello I, Valentinis B, Russo V, Lollini PL, Traversari C. Tanzarella S, et al. Among authors: russo v. Cancer Immunol Immunother. 2004 Jun;53(6):519-24. doi: 10.1007/s00262-003-0484-6. Epub 2004 Jan 16. Cancer Immunol Immunother. 2004. PMID: 14727086 Free PMC article.
1,428 results